JP2023538520A5 - - Google Patents

Info

Publication number
JP2023538520A5
JP2023538520A5 JP2023507879A JP2023507879A JP2023538520A5 JP 2023538520 A5 JP2023538520 A5 JP 2023538520A5 JP 2023507879 A JP2023507879 A JP 2023507879A JP 2023507879 A JP2023507879 A JP 2023507879A JP 2023538520 A5 JP2023538520 A5 JP 2023538520A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
patient
further characterized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023507879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538520A (ja
JP7846086B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045000 external-priority patent/WO2022032132A1/en
Publication of JP2023538520A publication Critical patent/JP2023538520A/ja
Publication of JP2023538520A5 publication Critical patent/JP2023538520A5/ja
Priority to JP2026060896A priority Critical patent/JP2026117027A/ja
Application granted granted Critical
Publication of JP7846086B2 publication Critical patent/JP7846086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023507879A 2020-08-07 2021-08-06 Ikaros又はaiolosによって媒介される障害に対する有利な治療法 Active JP7846086B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026060896A JP2026117027A (ja) 2020-08-07 2026-04-02 Ikaros又はaiolosによって媒介される障害に対する有利な治療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063063011P 2020-08-07 2020-08-07
US63/063,011 2020-08-07
US202163173160P 2021-04-09 2021-04-09
US63/173,160 2021-04-09
US202163212463P 2021-06-18 2021-06-18
US63/212,463 2021-06-18
PCT/US2021/045000 WO2022032132A1 (en) 2020-08-07 2021-08-06 Advantageous therapies for disorders mediated by ikaros or aiolos

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026060896A Division JP2026117027A (ja) 2020-08-07 2026-04-02 Ikaros又はaiolosによって媒介される障害に対する有利な治療法

Publications (3)

Publication Number Publication Date
JP2023538520A JP2023538520A (ja) 2023-09-08
JP2023538520A5 true JP2023538520A5 (cg-RX-API-DMAC7.html) 2024-08-15
JP7846086B2 JP7846086B2 (ja) 2026-04-14

Family

ID=80118544

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507879A Active JP7846086B2 (ja) 2020-08-07 2021-08-06 Ikaros又はaiolosによって媒介される障害に対する有利な治療法
JP2026060896A Pending JP2026117027A (ja) 2020-08-07 2026-04-02 Ikaros又はaiolosによって媒介される障害に対する有利な治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026060896A Pending JP2026117027A (ja) 2020-08-07 2026-04-02 Ikaros又はaiolosによって媒介される障害に対する有利な治療法

Country Status (12)

Country Link
US (1) US20230190760A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192450A4 (cg-RX-API-DMAC7.html)
JP (2) JP7846086B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230049678A (cg-RX-API-DMAC7.html)
CN (1) CN116194438B (cg-RX-API-DMAC7.html)
AU (1) AU2021322285B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002225A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173658A1 (cg-RX-API-DMAC7.html)
IL (1) IL300373A (cg-RX-API-DMAC7.html)
MX (1) MX2023001545A (cg-RX-API-DMAC7.html)
TW (1) TWI887465B (cg-RX-API-DMAC7.html)
WO (1) WO2022032132A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
KR102947433B1 (ko) * 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
SMT202600194T1 (it) * 2019-10-21 2026-05-12 Celgene Corp Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica
US11807620B2 (en) 2020-02-21 2023-11-07 Plexium, Inc. Quinazolinone compounds and related compounds
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
CA3194351A1 (en) * 2020-10-14 2022-04-21 Christopher G. Nasveschuk Tricyclic compounds to degrade neosubstrates for medical therapy
JP7863100B2 (ja) * 2020-10-14 2026-05-20 シーフォー セラピューティクス, インコーポレイテッド Ikzf2又はikzf4を分解する三環式リガンド
JP7807110B2 (ja) * 2021-08-27 2026-01-27 ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド イソインドリノン化合物およびその使用
JP2025505687A (ja) * 2022-02-09 2025-02-28 シーフォー セラピューティクス, インコーポレイテッド Cft7455のモルフィック形態及びその製造方法
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024193641A1 (zh) * 2023-03-21 2024-09-26 上海超阳药业有限公司 异吲哚啉衍生物和苯并吲哚衍生物及其应用
JP2026524477A (ja) 2023-06-30 2026-07-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Krasの分解のためのヘテロ二官能性化合物
CN122206684A (zh) 2023-06-30 2026-06-12 默克专利有限公司 用于kras蛋白降解的异双功能化合物
CN121620373A (zh) * 2024-07-26 2026-03-06 上海超阳药业有限公司 苯并吲哚衍生物的药物组合物、制备方法及用途
WO2026065268A1 (en) * 2024-09-29 2026-04-02 Biofront Ltd Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same
WO2026139448A1 (en) 2024-12-23 2026-07-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
CN120138159A (zh) * 2025-04-30 2025-06-13 徐州医科大学 Nup35基因作为胶质母细胞瘤诊断、预后及治疗靶点的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175481A1 (en) * 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
CN111662226B (zh) * 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
EP4717317A3 (en) * 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN111902141A (zh) * 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
US10905684B2 (en) 2018-06-13 2021-02-02 Biotheryx, Inc. Aminoamide compounds
KR102947433B1 (ko) * 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제

Similar Documents

Publication Publication Date Title
Eshghpour et al. Effect of menstrual cycle on frequency of alveolar osteitis in women undergoing surgical removal of mandibular third molar: a single-blind randomized clinical trial
Grushka et al. Burning mouth syndrome
Rieke et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials
Persson et al. Influence of Parkinson's disease on oral health
JP6891385B2 (ja) トラジピタントによる治療方法
Pereira et al. Effect of preemptive analgesia with ibuprofen in the control of postoperative pain in dental implant surgeries: a randomized, triple-blind controlled clinical trial
Xia et al. Expert consensus on the prevention and treatment of radiochemotherapy-induced oral mucositis
Paiva-Oliveira et al. Comparison of the anti-inflammatory effect of dexamethasone and ketorolac in the extractions of third molars
Bhadage et al. Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis
JP2024516795A (ja) エベロリムスおよびアムセネストラントを含む組合せ物
Ideo et al. Prevalence of apical periodontitis in patients with autoimmune diseases under immunomodulators: a retrospective cohort study
CN110013478A (zh) 用于抗肿瘤试剂施用的方法
Scott et al. Donor site wound healing following free gingival graft surgery using platelet rich fibrin: A randomized controlled trial
Çankaya et al. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study
Bhatia et al. Topical phenytoin suspension and normal saline in the treatment of leprosy trophic ulcers: a randomized, double‐blind, comparative study
JP2025505687A5 (cg-RX-API-DMAC7.html)
Kalogirou et al. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus
Lee et al. Extraction of mandibular third molars: relationship of preoperative anxiety with body mass index, serum high-sensitivity C-reactive protein levels, and visual analog scale scores and predictors of postoperative complications
Jivanescu et al. Effects of a Hydrogel Patch on Denture‐Related Traumatic Ulcers; an Exploratory Study
Eslamian et al. The effect of naproxen patches on relieving orthodontic pain by evaluation of VAS and IL-1β inflammatory factor: a split-mouth study
Meaney et al. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication
Alexander Clinical experience with naproxen in rheumatoid arthritis
Gusmão et al. Evaluation of a mucoadhesive pilocarpine tablet for the treatment of xerostomia: A randomized, double-blind, crossover clinical trial
Deen et al. Successful treatment of recurrent aphthous ulcers with nicotine lozenges in a lifelong non-smoker.
JPH0276813A (ja) 神経変性疾患の治療薬